Last reviewed · How we verify
NCT04078711: CHAIR
Chinese Medicine Treat for Hypertensive Renal Injury
Phase 2, PHASE3 trial testing Losartan 100Mg Tab in Hypertension in 520 participants. Status unknown.
30 June 2021
Quick facts
| Lead sponsor | Jiangsu Province Hospital of Traditional Chinese Medicine |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 520 |
| Start date | 10 September 2019 |
| Primary completion | 30 June 2021 |
| Estimated completion | 30 December 2021 |
Drugs / interventions tested
- Losartan 100Mg Tab — full drug profile →
- Qianyangyuyin 20g Granule — full drug profile →
- placebo
Conditions studied
- Hypertension — all drugs for Hypertension →
- Renal Injury — all drugs for Renal Injury →
Sponsor
Jiangsu Province Hospital of Traditional Chinese Medicine
Who can join
Adults 35 to 55, any sex, with Hypertension or Renal Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates whether the traditional chinese medicine (Qianyangyuyin formula) could prevent and treat early renal injury in patients with hypertension and microalbuminuria (defined as a urinary albumin to creatinine ratio between 30 and 300 mg/g) based on standard antihypertensive treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04078711
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other Jiangsu Province Hospital of Traditional Chinese Medicine trials
Trials by the same sponsor.
- NCT07335237 — Clinical Study on the Prevention and Treatment of Postoperative Gastrointestinal Dysfunction by Acupuncture Under ERAS M · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04078711 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu Province Hospital of Traditional Chinese Medicine
- Last refreshed: 6 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04078711.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing